ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine bioethics obesity cancer

Fighting the 10/90 Gap
Ricki Lewis | May 12, 2002 | 5 min read
While wealthy nations pursue drugs to treat baldness and obesity, depression in dogs, and erectile dysfunction, elsewhere millions are sick or dying from preventable or treatable infectious and parasitic diseases.1 It's called the 10/90 gap. "Less than 10% of the worldwide expenditure on health research and development is devoted to the major health problems of 90% of the population," explains Els Torreele, co-chair of a working group that provided background recently for an initiative announced
Notebook
The Scientist Staff | Oct 12, 1997 | 7 min read
Table of Contents NRC Denies Poisened Postdoc's Request No Human Clones A Funny Spin to Science Anti-Obesity Drug Withdrawn Haverford Finds Friend in Science More Than Padded Cells Cancer Checkpoint Super Grant STILL A MYSTERY: The identity of the person who poisoned Maryann Wenli Ma and Bill Wenling Zheng, shown here with their son, remains unknown. On September 17, the Nuclear Regulatory Commission (NRC) turned down a petition by Maryann Wenli Ma, the visiting Chinese postdoc at the Natio
Notebook
Eugene Russo | Dec 5, 1999 | 7 min read
Contents Pivotal pump Leptin limbo Clue to obesity Biotech Web site Helping hand Mapping malaria Notebook Pictured above are pigmented bacterial colonies of Deinococcus radiodurans, the most radiation-resistant organism currently known. DEINO-MITE CLEANUP In 1956, investigators discovered a potentially invaluable cleanup tool in an unlikely place. A hardy bacterium called Deinococcus radiodurans unexpectedly thrived in samples of canned meat thought to be sterilized by gamma radiation. The b
Cannabinoid controversy
Tia Ghose | Sep 9, 2009 | 5 min read
Receptors that bind the active ingredient in marijuana may be novel therapeutic targets in autoimmune disease, but contested evidence for their presence on neurons could hamper drug development
Opinion: Consumer DNA Testing Is Crossing into Unethical Territories
John D. Loike | Aug 16, 2018 | 4 min read
Data don’t support many direct-to-consumer products, from telomere assessments to bespoke diets based on genetic sequences.
Research Notes
Nadia Halim | Sep 3, 2000 | 5 min read
Stopping Ebola in Its Tracks Richard Preston brought the threat of emerging infectious diseases to the consciousness of his readers in The Hot Zone. The book graphically describes how the Ebola virus causes massive internal bleeding, which kills up to 90 percent of the people it infects. Now National Institutes of Health scientists are making promising advances to stop disease spread. Researchers have identified a viral protein that destroys endothelial cells, the cells that line the blood vess
Week in Review: October 5–9
Tracy Vence | Oct 8, 2015 | 2 min read
This year’s Nobel Prizes; toward developing a brown fat-activating drug; certain antioxidants can increase the spread of melanoma in mice; anonymity and post-publication peer review
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.
Cloning Capsized?
Ted Agres | Aug 19, 2001 | 10+ min read
Biopharmaceutical researchers fear how pending federal legislation outlawing the cloning of human cells will restrict their abilities to find cures for major degenerative diseases.1,2 Some also see lawmakers impinging on established nonhuman cloning techniques essential for the discovery of new drugs and therapies. The source of all this worry? The US House of Representatives passed July 31 by a wide margin a bill (H.R. 2505) sponsored by Reps. David Weldon (R-Fla.) and Bart Stupak (D-Mich.) th
Biotech Faces Evolving Patent System
Douglas Steinberg | Mar 5, 2000 | 8 min read
Like medieval alchemists, modern biologists apply intricate, esoteric protocols to lowly matter, such as bacteria and rodents. Unlike alchemists, biologists successfully transmute these creatures into gold--disease-fighting pharmaceuticals and profits accruing from them. An indispensable ingredient in this dross-to-drug process is patent protection, which preserves monopoly and attracts investment. Unfortunately, the patent system isn't as ideal a catalyst as the chimerical philosopher's stone s

Run a Search

ADVERTISEMENT